問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Dermatology

MacKay Memorial Hospital

Division of Dermatology

更新時間：2023-09-19

蕭百芬
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蕭百芬

MacKay Memorial Hospital

Division of Dermatology

List

12Cases

2025-02-01 - 2025-08-05

Completed
A multinational, multicenter, double-blind, placebo-controlled phase 2 trial evaluating the efficacy and safety of SAR444656 in adult subjects with moderate to severe atopic dermatitis.

  • Condition/Disease

    The study aimed to evaluate the efficacy of SAR444656 compared to placebo in treating AD lesions in adult subjects with moderate to severe AD. • Percentage change in EASI from baseline to week 16.

  • Test Drug

    SAR444656

Participate Sites
4Sites

Recruiting4Sites

2025-10-01 - 2028-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-10-01 - 2020-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-10-09 - 2020-12-10

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2023-02-01 - 2024-08-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-12-01 - 2027-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2026-06-01 - 2029-01-16

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2023-01-27 - 2025-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting2Sites

Terminated2Sites

2024-10-15 - 2027-12-20

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2027-12-31

Phase III

Active
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  • Condition/Disease

    Moderate to Severe Plaque Psoriasis

  • Test Drug

    N/A

Participate Sites
7Sites

Recruiting7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB